Arcturus Therapeutics Holdings Inc. (ARCT) Stock Grade

About Arcturus Therapeutics Holdings Inc.'s fundamentals

Arcturus Therapeutics is a biotechnology company with a market capitalization of $411.0 million that reported a significant net loss in its latest annual statement, reflected in a net margin of -97.9%. The company experienced a substantial decline in revenue, falling 51.4% year-over-year, indicating major challenges in its commercial operations or product performance. With no dividend yield and negative profitability metrics, the company is not currently generating earnings for shareholders. These financial indicators suggest Arcturus is in a development or transition phase typical of biotechnology firms, though its recent revenue contraction raises questions about near-term commercial viability.